Emyria is a company that accelerates treatment development for patients with unmet needs, is pleased to announce a partnership with Mind Medicine Australia to co-develop a gold-standard and data-driven clinical model for the safe provision of psychedelic-assisted therapies in Australia.

Emyria’s Managing Director, Dr Michael Winlo, said: “We’re delighted to support Mind Medicine Australia by developing a scalable psychedelic-assisted therapy care model for patients suffering from treatment resistant post-traumatic stress disorder, treatment resistant depression and substance abuse. Emyria has unique expertise caring for patients with unmet needs while also generating high quality clinical evidence using our RWE data platform.”

Read full announcement here